Dr Desiree Luthman's experience includes a series of roles leading regulatory affairs teams and strategies for pharmaceutical products spanning from early development to post-approval marketing.
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for respiratory diseases, has announced the appointment of Desiree Luthman, DDS to the Company's executive team as Vice President, Regulatory Affairs.
Dr Luthman's experience during the last two decades includes a series of roles leading regulatory affairs teams and strategies for pharmaceutical products spanning from early development to post-approval marketing. Throughout her career, Dr Luthman has held regulatory positions at large global pharmaceutical and biotechnology companies, including Bristol-Meyers Squibb, Celgene and AstraZeneca. Prior to joining Verona Pharma, Dr Luthman directed regulatory activities related to pulmonary disease at Sanofi and most recently led their regulatory team through the FDA approval of dupilumab for atopic dermatitis in the United States. Dr Luthman earned her Doctor in Dental Sciences from the Karolinska Institute in Sweden.
"We welcome Desiree to our growing Verona Pharma team," said Jan-Anders Karlsson, PhD, CEO of Verona Pharma. "She has an accomplished track record of working closely with the FDA and EMA on behalf of international healthcare companies to achieve key regulatory milestones. Her vast experience will be instrumental as we advance our regulatory plans in the U.S. and Europe under her leadership in our effort to deliver important new therapies to patients with respiratory diseases."
